NCT01257867

Brief Summary

This study investigates the effects of daily use of lithia water on blood tests of neuronal oxidative stress, mood, and well-being. Lithia water is a type of pure spring water containing trace levels of lithium, which is a naturally occurring mineral. Neuronal oxidative stress is caused by normal chemical reactions in the human body that sometimes result in damage to brain cells. Participation in this study will last for 8 weeks and includes daily use of study water for drinking. The primary objective of this pilot study is to test the hypothesis that, in healthy male participants, daily use of lithia water will improve neurogenesis and antioxidant capacity as measured by serum levels of brain-derived neurotrophic factor (BDNF) and oxidative stress markers. Secondary objectives will include examining self-reported changes in mood, cognition, and well-being.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2011

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 8, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 10, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2011

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2012

Completed
Last Updated

November 9, 2012

Status Verified

November 1, 2012

Enrollment Period

1.6 years

First QC Date

December 8, 2010

Last Update Submit

November 7, 2012

Conditions

Keywords

Brain-derived neurotrophic factorOxidative stressNeurogenesisLithiumLithia water

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline in BDNF levels at 4 weeks

    Blood samples will be assayed for brain-derived neurotrophic factor

    Baseline, Wk 4, Wk 8

Secondary Outcomes (3)

  • Standardized, validated questionnaires querying mood and quality of life

    Baseline, Wk 4, Wk 8

  • Standardized, validated questionnaires regarding cognitive functioning

    Baseline, Wk 4, Wk 8

  • Change from Baseline in oxidative stress protein markers at 4 weeks

    Baseline, Wk 4, Wk 8

Study Arms (2)

Lithia spring water

EXPERIMENTAL

Lithia water (active) for 4 weeks then placebo water for 4 weeks

Dietary Supplement: Lithia water

Natural spring water

PLACEBO COMPARATOR

Placebo water for 4 weeks then lithia water (active) for 4 weeks

Dietary Supplement: Natural spring water with negligible lithium levels

Interventions

Lithia waterDIETARY_SUPPLEMENT

Oral intake of approximately 2 litres (2L) daily for 4 weeks

Also known as: EDJ lithia spring water, (previous) Ilumati lithia spring water
Lithia spring water

Oral intake of approximately 2 litres (2L) daily for 4 weeks

Natural spring water

Eligibility Criteria

Age19 Years - 35 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male participants aged 19-35 years. \[Note: women are excluded in this pilot study because the variable effects of female sex hormones on oxidative stress markers and neurogenesis\];
  • No current, past or family history (in first-degree relatives) of a major psychiatric disorder or alcohol/substance abuse/dependence;
  • Non-smokers \[because smoking is associated with increased oxidative stress\];
  • No active medical condition (e.g., thyroid disease);
  • No regular use of prescribed or over-the-counter medications or illicit substances;
  • Negative urine drug-screening test; and
  • Competency to give informed consent.

You may not qualify if:

  • See above

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of British Columbia, Department of Psychiatry

Vancouver, British Columbia, V6T 2A1, Canada

Location

Related Links

Study Officials

  • Raymond W Lam, MD, FRCPC

    University of British Columbia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 8, 2010

First Posted

December 10, 2010

Study Start

March 1, 2011

Primary Completion

October 1, 2012

Study Completion

October 1, 2012

Last Updated

November 9, 2012

Record last verified: 2012-11

Locations